Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

Conditions:   Primary Renal Allograft Candidate;   Kidney Transplantation
Interventions:   Biological: Anti-thymocyte Globulin (Rabbit);   Biological: belatacept;   Drug: methylprednisolone;   Biological: basiliximab;   Drug: mycophenolate mofetil;   Drug: tacrolimus
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
Terminated - verified June 2016